Emily Mikhael

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASH23 #ASHKudos to @jmikhaelmd and @EmilyMikhael for hosting all of us today - and for such a sweet tribute in ASH News Daily today!

[Ruben A. Mesa, MD @mpdrc]

Running into my favorite “Mikhael” at #ASH23 outside yet another amazing, cutting edge, and clinically relevant @MedscapeOnc symposium on myelofibrosis! @EmilyMikhael @jmikhaelmd #WhereIsEmily? #MPNSM

[Emily Mikhael @EmilyMikhael]

@DrOlaLandgren @ASH_hematology What a fun way to start 2023 ASH! Hands down the best part of ASH is being able to catch up with friends. 🥰

[Emily Mikhael @EmilyMikhael]

@jmikhaelmd @mpdrc @IndyHematology The best part of ASCO is you!!! 🥰

[Emily Mikhael @EmilyMikhael]

@jmikhaelmd @szusmani The best part of ASH (besides the new data) is catching up with friends! So glad you two were able to enjoy the calm before the storm! Cheers!

[Emily Mikhael @EmilyMikhael]

@mpdrc @jmikhaelmd @ASH_hematology @Rfonsi1 @IMFmyeloma @cityofhope @TGen Such a thoughtful post, Ruben. ❤️ So excited to see Joe continue his diligent efforts serving at ASH!

[Ruben A. Mesa, MD @mpdrc]

Congrats to my amazing friend, inspirational leader & myeloma savant ⁦@jmikhaelmd⁩ on election next ⁦@ASH_hematology⁩ Treasurer! The field of hematology will be enriched by his passion and vision! ⁦@Rfonsi1⁩ ⁦@IMFmyeloma⁩ ⁦@cityofhope⁩ ⁦@TGen⁩

[Emily Mikhael @EmilyMikhael]

I am excited to join @medscape and @medscapecme for this discussion on the latest data and impacts in oncology. #OncTwitter
Register to watch here: https://t.co/veNlpar3IW

[Nina Shah @ninashah33]

Could not be happier for my big bro and #frientor @jmikhaelmd and @EmilyVanLaar #DMC @szusmani @Ccostello7 @rabonour1 @ZainabShd @Rfonsi1 #jemforever

[Emily Mikhael @EmilyMikhael]

@ninashah33 @Ccostello7 @DrOlaLandgren @MedscapeOnc Fantastic program - practical and insightful! Thanks to each one of you for your tireless dedication to patients with multiple myeloma!

[Nina Shah @ninashah33]

Basically the #ASH21 after-party... Loved hanging with my #myelebrities @Ccostello7 and @DrOlaLandgren for @MedscapeOnc Live Stream Across the Treatment Continuum: Case Challenges in Multiple Myeloma

[Medscape Education @MedscapeCME]

Finding the Right Fit: New Approaches in the Treatment of SCLC https://t.co/wiA5lrYM9Q

[Alnylam Pharmaceuticals @Alnylam]

We are pleased to share @US_FDA has accepted the New Drug Application (NDA) for patisiran, our investigational #RNAi therapeutic for the treatment of #hATTR #amyloidosis, and granted it Priority Review Status. https://t.co/AjzXt3JxEt

[Medscape @Medscape]

The most intriguing clinical trials presented in the field of #leukemia at #ASH17: https://t.co/wQQYYNXxE7

[Medscape Oncology @MedscapeOnc]

Here are the top 10 innovations poised to change medicine in 2018: https://t.co/B4ZRwKNVK7

[Medscape Education @MedscapeCME]

Case Studies in Carcinoid Syndrome: Optimizing Patient Quality of Life - with Dr. Pamela L. Kunz, MD https://t.co/5VxUBpcwe8

[Medscape Oncology @MedscapeOnc]

Hope may be on the horizon for AML patients after an early-phase trial showed "remarkable" results from drug combo: https://t.co/q25UVWyALQ

[Medscape Oncology @MedscapeOnc]

How to approach MGUS diagnosis when there is surprisingly little evidence to inform clinical practice: https://t.co/tfRFTChICD

[Medscape Oncology @MedscapeOnc]

50% of #cancer patients struggle to make sense of clinical trials: https://t.co/5DR2wfVwfv

[NEJM @NEJM]

Podcast: Tait Shanafelt, M.D., discusses causes of burnout and efforts to improve support for clinicians. Listen now: https://t.co/t3qcgxBmxL